Angiotensin III (human, mouse): A Core RAAS Peptide for Cardiovascular and Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) is a hexapeptide (Arg-Val-Tyr-Ile-His-Pro-Phe) generated via N-terminal cleavage of angiotensin II and mediates about 40% of angiotensin II's pressor activity while fully stimulating aldosterone release (Oliveira et al., 2025). It acts via AT1 and AT2 receptors, with preferential activation of AT2R, and exogenous administration suppresses renin while increasing aldosterone in vivo [DOI]. The peptide is highly soluble in water, ethanol, and DMSO, and is validated for cardiovascular and neuroendocrine signaling research (APExBIO A1043). Recent studies highlight its role in modulating receptor interactions relevant to infectious and hypertensive disease models. Correct storage and handling are critical for assay reproducibility and data reliability.

Biological Rationale

Angiotensin III (human, mouse) is a central member of the renin-angiotensin-aldosterone system (RAAS), a regulatory cascade essential for blood pressure, electrolyte balance, and fluid homeostasis (Oliveira et al., 2025). The peptide is produced by enzymatic N-terminal cleavage of angiotensin II, predominantly in erythrocytes and peripheral tissues. Angiotensin III retains full aldosterone-stimulating capacity, crucial for sodium retention and vascular tone (see summary). It mediates about 40% of the pressor response induced by angiotensin II, validating its use as a cardiovascular research peptide. Unlike angiotensin II, angiotensin III displays enhanced relative specificity for the AT2 receptor subtype, which confers distinct physiological effects such as vasodilation and anti-proliferative signaling.

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III binds to both AT1 and AT2 receptor subtypes, acting as a ligand that triggers receptor-mediated signaling pathways. The peptide’s sequence (Arg-Val-Tyr-Ile-His-Pro-Phe) determines its receptor affinity and downstream effects (see structure/mechanism). Upon AT1R activation, angiotensin III induces vasoconstriction, increases aldosterone secretion, and suppresses renin release—a profile paralleling but not identical to angiotensin II. Preferential engagement of AT2R leads to vasodilatory, anti-inflammatory, and anti-fibrotic effects [DOI]. In rodent brain models, intracerebroventricular injection of angiotensin III elicits strong pressor and dipsogenic responses. Its full aldosterone-stimulating activity is attributed to direct adrenal cortex signaling, and suppression of renin is achieved via negative feedback on the juxtaglomerular apparatus.

Evidence & Benchmarks

• Angiotensin III (2–8) is generated in vivo from angiotensin II (1–8) via aminopeptidase A activity (Oliveira et al., 2025).
• It accounts for approximately 40% of the pressor activity of angiotensin II under physiological conditions (DOI:10.3390/ijms26136067).
• Angiotensin III retains full aldosterone-releasing capacity in adrenal cortex assays (Oliveira et al., 2025).
• Exogenous angiotensin III suppresses renin release in vivo, mirroring angiotensin II effects (Angiotensin III: Structure, Mechanism).
• Angiotensin III exhibits high solubility: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO (APExBIO A1043).
• It is stable when stored desiccated at -20°C; prolonged storage in solution reduces reliability (APExBIO datasheet).
• Angiotensin III potentiates AXL receptor–SARS-CoV-2 spike binding, similar to other short angiotensin peptides (Oliveira et al., 2025, Table 2).

Compared to the overview in "Core RAAS Peptide for Cardiac Models", this article details the experimental validation and handling parameters specific to SKU A1043, emphasizing recent infectious disease insights.

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is indispensable for:

• Cardiovascular research: Modeling hypertension and evaluating AT1/AT2 receptor antagonists.
• Neuroendocrine studies: Probing dipsogenic and pressor responses in rodent brain models.
• Endocrine signaling: Assaying aldosterone and renin modulation in adrenal and renal systems.
• Infectious disease research: Investigating peptide-mediated modulation of viral receptor binding (Oliveira et al., 2025).

For advanced guidance on protocol optimization in RAAS peptide modeling, see "Optimizing RAAS Research"; this article extends that foundation by detailing vendor-specific stability and solubility benchmarks for APExBIO's A1043 peptide.

Common Pitfalls or Misconceptions

• Angiotensin III is not interchangeable with angiotensin II for all receptor studies: it has distinct AT2R specificity and fewer pro-fibrotic effects.
• Storing the peptide in aqueous solution for extended periods degrades activity; always store desiccated at -20°C (APExBIO).
• Its pressor activity is only partial relative to angiotensin II; do not use as a 1:1 substitute in hypertension models (Oliveira et al., 2025).
• Not all commercially available peptides match the solubility or purity standards of APExBIO A1043; vendor selection impacts reproducibility (see Q&A).
• Angiotensin III does not directly inhibit SARS-CoV-2 infection, but may modulate receptor binding relevant for viral entry (Oliveira et al., 2025).

Workflow Integration & Parameters

APExBIO's Angiotensin III (human, mouse) (SKU A1043) is provided as a solid (MW 931.09; C46H66N12O9), with validated solubility in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), and DMSO (≥93.1 mg/mL). For optimal stability, reconstitute immediately before use and store aliquots desiccated at -20°C. Long-term storage in solution is not recommended. The peptide is compatible with both in vivo (rodent) and in vitro (cell culture) models targeting AT1/AT2 receptor pathways. Workflow integration guidance, including troubleshooting for solubility and batch consistency, is provided in this scenario-driven guide, which this article updates with 2025 literature and infectious disease relevance.

Conclusion & Outlook

Angiotensin III (human, mouse) is a validated, high-performance peptide for dissecting RAAS mechanisms in cardiovascular, neuroendocrine, and emerging infectious disease models. Its partial pressor activity, full aldosterone-stimulating potency, and AT2R specificity make it indispensable for mechanistic and translational research. APExBIO's SKU A1043 sets the benchmark for solubility and reproducibility in RAAS peptide workflows. Ongoing research into peptide-mediated modulation of viral receptor interactions further expands its experimental relevance, supporting the design of next-generation disease models and therapeutic screens.